Venture Life Group PLC Appointment of Joint Broker (7300S)
13 Luglio 2020 - 8:00AM
UK Regulatory
TIDMVLG
RNS Number : 7300S
Venture Life Group PLC
13 July 2020
13 July 2020
Venture Life Group plc
("Venture Life" the "Company" or the "Group")
Appointment of N+1 Singer as Joint Broker
Venture Life Group plc (AIM: VLG), a leader in developing,
manufacturing and commercialising products for the international
self-care market, announces the appointment of N+1 Singer as Joint
Broker effective immediately. Cenkos Securities plc will continue
as the Company's Nominated Adviser and Joint Broker.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Andrew Waters, Chief Financial Officer
Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397 8900
Stephen Keys / Mark Connelly / Cameron MacRitchie (Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
+44 (0) 20 7496
N+1 Singer (Joint Broker) 3000
Shaun Dobson / Carlo Spingardi
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, The
Netherlands and Italy, the Group's product portfolio includes some
key products such as the UltraDEX and Dentyl oral care product
ranges, food supplements for maintaining brain function, medical
devices for women's intimate healthcare, fungal infections and
proctology, and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands,
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies for consumer healthcare products, primarily
medical devices.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPDBLFFBDLEBBV
(END) Dow Jones Newswires
July 13, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024
